Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade. Research head Lange said the drugmaker could launch the pill version of its experimental weight loss drug amycretin this decade. It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles